Epilepsy Foundation: 2017 New Therapy Commercialization Grant Program

The Epilepsy Foundation is accepting letters of intent that will drive the development of new therapies for epilepsy, accelerating the advancement of research from the laboratory to the patient. Funding is provided to academic and commercial groups. The program seeks to advance the development of new therapies, including but not limited to medicines, biologics or devices. The award amount varies. Submission deadline March 10.

Epilepsy Foundation: 2017 New Therapy Commercialization Grant Program
http://www.epilepsy.com

The Epilepsy Foundation is accepting Letters of Intent (LOIs) that will drive the development of new therapies for epilepsy, accelerating the advancement of research from the laboratory to the patient. Funding is provided to academic and commercial groups. The program seeks to advance the development of new therapies, including but not limited to medicines, biologics or devices. All proposals must demonstrate a clear path from the lab to the patient and are evaluated with consideration for their potential value to patients, likelihood of successful development including regulatory approval and the timeframe of development. The Program encourages 1:1 matching grants to academic and commercial entities to support the commercialization of novel approaches to the treatment of epilepsy. Preference will be given to proposals that already have a commercial partner engaged to assist with development, and to proposals that have committed or matched funding from a sponsoring institution, commercial partner or other third party source. Areas of interest include: novel approaches to treatment; Platform technology to advance screening techniques that can be utilized by multiple laboratories, including utility of techniques for early proof-of-concept trials; and, adaptation of treatment in development for another therapeutic area to assess utility for epilepsy (while maintaining patent protection). Investigators must hold a relevant advanced degree (M.D., and/or Ph.D.), and have completed all research training.

LOI Deadline: March 10, 2017 by 11:59pm EST. Invited full proposals will be due May 5, 2017 by 11:59pm EST. Application Guidelines for the award: http://www.epilepsy.com/accelerating-new-therapies/our-research-program/research/new-therapy-commercialization-grant-program/guidelines

The UNC Office of Corporate and Foundation Relations is available to provide assistance in pursuing privately funded opportunities. If you have any questions about this funding opportunity, please email cfr@unc.edu or phone 919.962.2867.

Filed under: